Epidauros and InPheno to Co-Market Their PGx Services

Dec 01, 2006

NEW YORK (GenomeWeb News) — Epidauros and InPheno earlier this week said they plan to co-market their pharmacogenomic and phenotypic services to drug developers as a single service.

“We are trying to bring both genotype and phenotype analysis together because genetic analysis alone is not sufficient to predict statistical variance in clinical outcomes,” Hans Peter Arnold, director of business development and marketing at Epidauros, told GenomeWeb News this week.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Penguins With Roving Eyes

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Funding Lost

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

This Week in Science

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

New Framework Suggested

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

Main menu